Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.
The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 66 |
| CEO | Amy L. Burroughs M.B.A. |
Contact Details
Address: 1065 East Hillsdale Boulevard Foster City, California United States | |
| Website | https://www.ternspharma.com |
Stock Details
| Ticker Symbol | TERN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831363 |
| CUSIP Number | 880881107 |
| ISIN Number | US8808811074 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy L. Burroughs M.B.A. | Chief Executive Officer & Director |
| Dr. Mark Joseph Vignola Ph.D. | Chief Financial Officer & Treasurer |
| Elona Kogan Esq., J.D. | Chief Legal Officer |
| David Eric Strauss | Vice President of Finance & Controller |
| Debra Sieminski | Senior Vice President of Medical Affairs |
| Dr. Emil T. Kuriakose M.D. | Chief Medical Officer |
| Dr. Jeffrey R. Jasper Ph.D. | Senior Vice President of Research |
| Melita Sun Jung | Chief Business Officer |
| Scott Harris | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Jan 06, 2025 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 4 | Filing |
| Nov 19, 2024 | 3 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |